1.
In the article entitled “Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta‐analysis” in Table 1, the availability of amisulpride in Japan was labelled incorrectly. The correct table is shown below.
TABLE 1.
Availability of amisulpride in different countries
| Country | Availability (psychiatric indication) |
|---|---|
| Europe | AMS is indicated for the treatment of acute or chronic schizophrenic disorders in the following countries:‐ Austria‐ Belgium‐ Bulgary‐ Croatia‐ Cyprus‐ Czech Republic a (dysthymia)‐ Denmark‐ Estonia‐ France‐ Germany‐ Greece‐ Iceland‐ Italy a (dysthymia)‐ Latvia‐ Lithuania‐ Luxembourg‐ Norway‐ Poland‐ Portugal a (dysthymia)‐ Romania‐ Slovakia‐ Slovenia‐ Spain‐ Switzerland‐ UK |
| US b | Not available |
| Canada | Not available |
| Japan | Not available |
| China | Available (acute or chronic schizophrenic disorders) |
| Russia | Available (acute or chronic schizophrenic disorders) |
AMS is licensed for dysthymia only in some european countries (e.g. Italy, Czech Republic, Portugal) (Rittmansberger et al., 2019).
Approved for use in the United States in February 2020 only for treatment and prevention of Postoperative Nausea and Vomiting.
Sources: European Medicines Agency (2020), Food and Drugs Administration (2020), National Centres for Advancing Translational Sciences (2020), drugs.com (2020), Generic Drugs (2018).
The authors apologize for the mistake and inconvenience this may cause.
REFERENCE
- Zangani, C. , Giordano, B. , Stein, H.‐C. , Bonora, S. , D'Agostino, A. , & Ostinelli, E. G. (2021). Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta‐analysis. Human Psychopharmacology: Clinical and Experimental, 36(6), e2801. 10.1002/hup.2801 [DOI] [PMC free article] [PubMed] [Google Scholar]